ONO-8577-02 Phase2a

Phase 2a exploratory, randomized, double-blind, parallel-group study of ONO-8577 compared to combination of solifenacin succinate/ mirabegron for overactive bladder

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223480

Enrollment

200

Registered

2017-03-15

Start date

2017-03-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive bladder

Interventions

investigational material(s) Generic name etc : ONO-8577 INN of investigational material : Therapeutic category code : 251 Agents affecting urinary organs Dosage and Administration for Investigational

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Sexes: Both 2. Ages: 20 years to 80 years 3. Patient with symptoms of overactive bladder for >=6 months

Exclusion criteria

Exclusion criteria: 1. Patient with genuine stress incontinence, or with stress-predominant mixed urinary incontinence 2. Patient who has never experienced urge urinary incontinence during disease duration of overactive bladder

Design outcomes

Primary

Measure	Time frame
Efficacy	—

Secondary

Measure	Time frame
Safety, Pharmacokinetics	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026